ALK-Abelló A/S
ALK-B
Ранг среди акций
#2416
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Цена акции
$36.42
Рыночная капитализация
$8.08B
Изменение (1 день)
-3.54%
Изменение (1 год)
10.29%
Страна
DK
Торговля ALK-Abelló A/S (ALK-B)
Категория
Healthcare
Выручка компании ALK-Abelló A/S (ALK-B)
Выручка на Jun 2026 TTM: $1.08B
Согласно последним финансовым отчетам ALK-Abelló A/S, текущая выручка компании (TTM) составляет $1.08B. В 2023 году компания получила выручку $714.26M больше, чем выручке в 2022 году, которая составила $649.28M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки ALK-Abelló A/S с 2004 по 2026
Выручка на конец каждого года
| Год | Выручка | Изменить |
|---|---|---|
| 2026 (TTM) | $1.08B | 40.35% |
| 2024 | $772.54M | 8.16% |
| 2023 | $714.26M | 10.01% |
| 2022 | $649.28M | 8.42% |
| 2021 | $598.86M | 4.50% |
| 2020 | $573.06M | 16.63% |
| 2019 | $491.36M | 9.76% |
| 2018 | $447.68M | -4.54% |
| 2017 | $468.95M | 9.96% |
| 2016 | $426.48M | 13.93% |
| 2015 | $374.34M | -5.40% |
| 2014 | $395.69M | -4.38% |
| 2013 | $413.80M | -0.22% |
| 2012 | $414.70M | 1.41% |
| 2011 | $408.93M | 5.61% |
| 2010 | $387.20M | 3.63% |
| 2009 | $373.63M | 12.03% |
| 2008 | $333.50M | 2.67% |
| 2007 | $324.83M | 23.62% |
| 2006 | $262.76M | 36.41% |
| 2005 | $192.63M | -76.45% |
| 2004 | $817.87M | 0.00% |
Выручка аналогичных компаний или конкурентов
| Компания | Выручка | Разница в выручке | Страна |
|---|---|---|---|
| $12.62B | 1,064.32% |
US
|
|
| $2.23B | 105.49% |
US
|
|
| $15.74B | 1,352.08% |
AU
|
|
| $6.02B | 455.34% |
NL
|
|
| - | - |
CH
|
